Atara Biotherapeutics
Atara Biotherapeutics' revenue fell 6.3% to $121 million in fiscal 2025. Its operating margin was 29.7%, up from −64.7% a year earlier. Free cash flow was −$51 million. The diluted share count rose 69.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Atara Biotherapeutics does
Atara Biotherapeutics develops cell therapies made from donated immune cells called T cells. Its one approved product, Ebvallo (tab-cel), treats a rare and aggressive cancer, EBV+ PTLD, that can follow an organ or stem cell transplant when the Epstein-Barr virus gets out of control in patients with weakened immune systems. Because the cells come from donors and are made ahead of time, a dose can be taken from stock rather than built from each patient's own cells. Ebvallo is approved in the European Economic Area, the UK and Switzerland, but not in the U.S.
Atara does not sell Ebvallo itself. A French drugmaker, Pierre Fabre, holds the worldwide rights and now handles the medicine's manufacturing, trials and dealings with regulators at its own cost. Atara earns milestone payments and royalties on sales, and has sold part of its European royalties to an investor, HCRx. Atara is eligible for up to $556.0 million in further milestone payments outside the original European territory, if certain goals are met.
The U.S. Food and Drug Administration turned down the application to sell tab-cel twice: in January 2025 over a manufacturing site, and in January 2026 because it no longer accepted the main trial as adequate evidence. In 2025 Atara stopped its other programs, cut its staff to about 15 employees, and began looking at options such as a merger or a sale of assets.
Its biggest risks, as it describes them
- Its business depends almost entirely on one product, tab-cel, which the FDA has turned down twice in the U.S.
- It relies on Pierre Fabre to make, test, win approval for and sell tab-cel, and Pierre Fabre could fall short.
- It has lost money since it began and needs new financing soon, which could force it to wind down.
- Its search for a merger, sale or other deal may not succeed or may not deliver the benefits it hopes for.
- Manufacturing donor-cell therapies is complex, and problems at partners' plants could cut supply.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 371 | 243 | 52 | 42 | 8 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −10,639.4x | −752.0x | −52.2x | −18.1x | 9.5x |
| Current ratio | 3.6x | 3.7x | 0.7x | 0.5x | 0.8x |
| Quick ratio | 3.6x | 3.7x | 0.7x | 0.4x | 0.8x |
Cash flow
Projections
Project Atara Biotherapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $5.7 million of Atara Biotherapeutics shares on the open market, and 4 insiders sold $3.8 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | AnhCo NguyenPresident and CEO, Director | Sold | 6,094 | $6.46 | $39,368 | Form 4 |
| Sep 4, 2026 | Brian N CherryDirector | Bought | 104,166 | $9.60 | $999,994 | Form 4 |
| Aug 17, 2026 | AnhCo NguyenPresident and CEO, Director | Sold | 5,062 | $8.08 | $40,901 | Form 4 |
| May 18, 2026 | AnhCo NguyenPresident and CEO, Director | Sold | 5,241 | $9.13 | $47,850 | Form 4 |
| May 18, 2026 | Yanina Grant-HuertaChief Accounting Officer | Sold | 2,414 | $9.13 | $22,040 | Form 4 |
| May 7, 2026 | EcoR1 Capital LLC10% owner | Bought | 507,407 | $9.35 | $4.7 million | Form 4 |
| May 7, 2026 | Panacea Innovation Ltd10% owner | Sold | 313,446 | $10.10 | $3.2 million | Form 4 |
| Mar 2, 2026 | AnhCo NguyenPresident and CEO, Director | Sold | 2,996 | $5.09 | $15,247 | Form 4 |
| Mar 2, 2026 | Yanina Grant-HuertaChief Accounting Officer | Sold | 2,104 | $5.08 | $10,688 | Form 4 |
| Jan 12, 2026 | James HuangDirector, 10% owner | Sold | 80,554 | $6.07 | $488,963 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −2,351.8% | 1,350.5% | −48.5% |
| Altman Z'' | −51.20 | −71.22 | −315.39 |
| Accruals ratio | −30.7% | −12.2% | 129.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Atara Biotherapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Atara Biotherapeutics | FY25 | −6.3% | 29.7% | −42.2% | — | — | — | |
| Monte Rosa Therapeutics | FY25 | 63.5% | −43.8% | −22.2% | — | — | — | Compare |
| Xencor | FY25 | 13.7% | −141.3% | −110.1% | −19.9% | — | 3 | Compare |
| Agenus | FY25 | 10.4% | −17.7% | −67.6% | — | — | 3 | Compare |
| ImmunityBio | FY25 | 668.3% | −226.0% | −272.6% | — | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | — | 64 | 9 | 129 | 121 |
| Revenue growth | — | — | — | — | — | — | — | −86.5% | 1,404.0% | −6.3% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 56 | 81 | 168 | 216 | 245 | 282 | 272 | 225 | 152 | 37 |
| Operating income | −81 | −122 | −237 | −296 | −309 | −340 | −280 | −276 | −83 | 36 |
| Net income | −79 | −120 | −231 | −291 | −307 | −340 | −228 | −276 | −85 | 33 |
| Diluted EPS (US$) | −68.75 | −100.00 | −131.75 | −141.75 | −103.75 | −90.75 | −56.00 | −65.19 | −11.41 | 2.57 |
| Diluted shares (millions) | 1 | 1 | 2 | 2 | 3 | 4 | 4 | 4 | 8 | 13 |
| Cash flow | ||||||||||
| Cash from operations | −60 | −88 | −180 | −236 | −181 | −220 | −270 | −193 | −69 | −51 |
| Capital expenditure | 3 | 20 | 36 | 6 | 4 | 11 | 4 | 1 | 0 | 0 |
| Free cash flow | −63 | −108 | −216 | −241 | −185 | −231 | −275 | −194 | −69 | −51 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 17 | 23 | 34 | 52 | 51 | 54 | 54 | 45 | 27 | 10 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 256 | 166 | 310 | 259 | 501 | 371 | 243 | 52 | 42 | 8 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 264 | 218 | 392 | 343 | 588 | 468 | 376 | 166 | 109 | 20 |
| Total liabilities | 10 | 40 | 53 | 52 | 126 | 188 | 250 | 265 | 206 | 59 |
| Shareholders' equity | 254 | 178 | 339 | 291 | 462 | 280 | 127 | 99 | −97 | −38 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −441.2% | −3,219.5% | −64.7% | 29.7% |
| Net margin | — | — | — | — | — | — | −359.1% | −3,220.9% | −66.2% | 27.1% |
| Free cash flow margin | — | — | — | — | — | — | −432.0% | −2,265.2% | −53.5% | −42.2% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | −2,351.8% | 1,350.5% | −48.5% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −27.8% | −55.4% | −89.2% | −92.4% | −81.4% | −91.7% | −112.4% | −244.5% | — | — |
| Return on assets | −26.9% | −49.6% | −75.7% | −79.2% | −65.9% | −64.4% | −54.1% | −101.9% | −62.2% | 50.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |